Gene Sequencing News and Research

RSS

MGI's DNBSEQ-T20×2 wins BEYOND Healthcare Innovation Award

MGI Tech Co. Ltd. ("MGI"), a company committed to building core tools and technology to lead life science, today is proud to announce that its DNBSEQ-T20×2 ("T20") gene sequencing platform has been awarded the BEYOND Healthcare Innovation Award.

From MGI 15 May 2023

Novel ingestible device enables non-invasive profiling of the gut microbiome, proteome, and metabolome

Researchers developed an ingestible device to collect samples from the human intestine.

12 May 2023

MGI launches overseas production line of DNBSEQ-G400* sequencer in Latvia

Riga, Latvia, 8 May 2023 – LATVIA MGI TECH, SIA, ("MGI Latvia") a subsidiary of MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technology to lead life science, today announced the official opening of its large-scale production line in Latvia. As MGI's largest regional hub for the European market, the facility based in Riga will see assembly and production of DNBSEQ-G400* gene sequencing instruments and HotMPS** reagents.

From MGI 10 May 2023

Advancing the development of vaccines through recombinant technology

In this interview, News-Medical talks to Dr. Amy Sheng, the head of CRO at Sino Biological, about current developments in the field of vaccine development through recombinant techniques.

From Sino Biological Inc. 4 May 2023

Parkinson's disease-like gut dysbiosis detected in early stages of the disease

Study aimed to investigate the gut microbiota composition in early Parkinson's disease (PD), REM sleep behavior disorder (RBD), first-degree relatives of RBD (RBD-FDR), and healthy controls.

4 May 2023

MGI secured first corporate order of ultra-high throughput sequencer DNBSEQ-T20×2*

Shanghai, China, April 25th, 2023 — MGI Tech Co., Ltd. (“MGI”), a company committed to building core tools and technology to lead life science, announced its partnership with Shanghai-based JMDNA Biomedical Technology Co., Ltd. (“JMDNA”) for DNBSEQ-T20×2 (“T20”), a sequencer that broke records for its ultra-high throughput and cost-efficiency. This was the first corporate order of the T20 sequencer that MGI has secured worldwide.

From MGI 27 Apr 2023

New insight on the uptick in colorectal cancer diagnoses and deaths among younger people

For years, colorectal cancer was believed by many to primarily impact older people; however, in recent years, there has been an uptick in colorectal cancer diagnoses and deaths among younger people ranging in age from their mid-20s to late 50s.

28 Feb 2023

Can the gut microbiota and metabolome explain variation in anti-SARS-CoV-2 vaccination responses in immunosuppressed IBD patients?

Researchers explored the connection between the metabolic function of the gut microbiota, its composition, and immune response to SARS-CoV-2 vaccination in IBD patients.

27 Feb 2023

Gut dysbiosis and sepsis susceptibility among pregnant women

Researchers describe the role of gut dysbiosis during pregnancy in promoting excessive macrophage pyroptosis, which increases vulnerability to sepsis.

19 Feb 2023

Complete genomics drops genome sequencing price to sub $100 at AGBT General Meetin

Complete Genomics Inc., a global life science tools leader and subsidiary of MGI Tech Co., Ltd. (“MGI”), today launched new revolutionary products and prices at Advances in Genome Biology and Technology (AGBT) General Meeting.

From MGI 14 Feb 2023

Complete Genomics drops genome sequencing price to sub $100 at AGBT general meeting

From Complete Genomics 9 Feb 2023

Complete Genomics Drops Genome Sequencing Price to Sub $100 at AGBT General Meeting

From Complete Genomics 9 Feb 2023

Deep-learning based filter removes false positives, improves the accuracy of cancer diagnosis

Next-generation cancer strategies rely on next-generation gene sequencing (NGS), which paves the way for new techniques and tools to detect mutations and determine patient therapy.

1 Feb 2023

Study demonstrates intrahost MPXV variation within a single lesion

Researchers reported on the clinical and molecular characteristics of MPXV infections in Finland.

31 Jan 2023

BGI cares - 2022 social responsibilities in review

At BGI Genomics, we believe it is our responsibility to not only enhance global health outcomes, but also to help make the places we work and live in better.

From BGI Genomics 20 Dec 2022

Study examines both the exterior surface and interior microbiome of mosquitoes

Avoiding mosquitoes to protect against bites is always a good idea. But a new North Carolina State University study shows that the bacteria-ridden exteriors of mosquitoes may be another reason to arm yourself with a swatter.

17 Dec 2022

Many genetic disorders respond well to specialized gene therapy

When the normal DNA sequence in an individual changes or mutates it can cause disease. The mutation may involve multiple genes and may be caused by environmental factors, or there may be chromosomal defects that are harmful at birth, in infancy or environment at a later stage.

12 Dec 2022

How two structurally different lemon pectins modulate the gut microbiota

A diet containing fruits and vegetables contains pectins (plant polysaccharides). Pectin cannot be metabolized by mammalian cells in the gastrointestinal tract but is fermented by the gut microbiota in the colon, where short-chain fatty acids (SCFAs) are released. Previous studies have examined pectin's prebiotic properties.

4 Dec 2022

The importance of early cancer screening

In this interview, Thomas Qiu, Senior Product Manager from BGI Genomics, talks to NewsMedical about current global cancer rates, and the importance of early cancer screening.

From BGI Genomics 1 Dec 2022

Study investigates microbial composition in bat lung tissue

Announcing a new article publication for Zoonoses journal. Bats are the hosts of multiple pathogens, but the microbial composition of their lung tissues remains unknown.

25 Nov 2022